{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T21:33:59Z","timestamp":1793223239007,"version":"4.5.0"},"reference-count":23,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T00:00:00Z","timestamp":1790121600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004329","name":"Slovenian Research and Innovation Agency","doi-asserted-by":"publisher","award":["P3-0343"],"award-info":[{"award-number":["P3-0343"]}],"id":[{"id":"10.13039\/501100004329","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004329","name":"Slovenian Research and Innovation Agency","doi-asserted-by":"publisher","award":["J7-70258"],"award-info":[{"award-number":["J7-70258"]}],"id":[{"id":"10.13039\/501100004329","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004329","name":"Slovenian Research and Innovation Agency","doi-asserted-by":"publisher","award":["V3-24038"],"award-info":[{"award-number":["V3-24038"]}],"id":[{"id":"10.13039\/501100004329","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004329","name":"Slovenian Research and Innovation Agency","doi-asserted-by":"publisher","award":["J3-2536"],"award-info":[{"award-number":["J3-2536"]}],"id":[{"id":"10.13039\/501100004329","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004329","name":"Slovenian Research and Innovation Agency","doi-asserted-by":"publisher","award":["J3-4525"],"award-info":[{"award-number":["J3-4525"]}],"id":[{"id":"10.13039\/501100004329","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004329","name":"Slovenian Research and Innovation Agency","doi-asserted-by":"publisher","award":["P3-0308"],"award-info":[{"award-number":["P3-0308"]}],"id":[{"id":"10.13039\/501100004329","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["atherosclerosis-journal.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Atherosclerosis"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.atherosclerosis.2026.121912","type":"journal-article","created":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T15:34:00Z","timestamp":1790177640000},"page":"121912","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Lipoprotein(a) reduction with PCSK9-targeting pharmacotherapy: A prospective real-world registry study"],"prefix":"10.1016","volume":"422","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-4159-1783","authenticated-orcid":false,"given":"Jan","family":"Kafol","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5736-8904","authenticated-orcid":false,"given":"Zlatko","family":"Fras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marko","family":"Novakovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matija","family":"Cevc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Krevel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lenart","family":"Kafol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anamarija","family":"Kelenc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klarisa","family":"Kepic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katarina","family":"Vrbinc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miha","family":"Svarc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Urh","family":"Groselj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Borut","family":"Jug","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"22","key":"10.1016\/j.atherosclerosis.2026.121912_bib1","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1016\/j.jacc.2025.08.015","article-title":"Global, regional, and national burden of cardiovascular diseases and risk factors in 204 countries and territories, 1990-2023","volume":"86","year":"2025","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"10.1016\/j.atherosclerosis.2026.121912_bib2","doi-asserted-by":"crossref","DOI":"10.3390\/jcm13051251","article-title":"Novel and emerging LDL-C lowering strategies: a new era of dyslipidemia management","volume":"13","author":"Agnello","year":"2024","journal-title":"J Clin Med"},{"issue":"1","key":"10.1016\/j.atherosclerosis.2026.121912_bib3","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1161\/ATVBAHA.118.311999","article-title":"Highlighting residual atherosclerotic cardiovascular disease risk","volume":"39","author":"Matsuura","year":"2019","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"39","key":"10.1016\/j.atherosclerosis.2026.121912_bib4","doi-asserted-by":"crossref","first-page":"3925","DOI":"10.1093\/eurheartj\/ehac361","article-title":"Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European atherosclerosis society consensus statement","volume":"43","author":"Kronenberg","year":"2022","journal-title":"Eur Heart J"},{"issue":"1","key":"10.1016\/j.atherosclerosis.2026.121912_bib5","doi-asserted-by":"crossref","first-page":"e48","DOI":"10.1161\/ATV.0000000000000147","article-title":"Lipoprotein(a): a genetically determined, causal, and prevalent risk factor for atherosclerotic cardiovascular disease: a scientific statement from the American heart association","volume":"42","author":"Reyes-Soffer","year":"2022","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"1","key":"10.1016\/j.atherosclerosis.2026.121912_bib6","first-page":"76","article-title":"Lipoprotein (a): structure, pathophysiology and clinical implications","volume":"103","author":"Maranhao","year":"2014","journal-title":"Arq Bras Cardiol"},{"key":"10.1016\/j.atherosclerosis.2026.121912_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.jacl.2026.03.019","article-title":"Lipoprotein(a) reduction with inclisiran, alirocumab, evolocumab, enlicitide, and lerodalcibep: a systematic review and meta-analysis of randomized controlled trials","author":"Mulligan","year":"2026","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.atherosclerosis.2026.121912_bib8","doi-asserted-by":"crossref","DOI":"10.3389\/fphys.2021.603910","article-title":"New insights into the regulation of lipoprotein metabolism by PCSK9: lessons from stable isotope tracer studies in human subjects","volume":"12","author":"Ying","year":"2021","journal-title":"Front Physiol"},{"issue":"4","key":"10.1016\/j.atherosclerosis.2026.121912_bib9","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1161\/CIRCULATIONAHA.116.025253","article-title":"Effects of PCSK9 inhibition with alirocumab on lipoprotein metabolism in healthy humans","volume":"135","author":"Reyes-Soffer","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2026.121912_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.atherosclerosis.2025.120420","article-title":"Effect of lipid-lowering therapies on lipoprotein(a) levels: a comprehensive meta-analysis of randomized controlled trials","volume":"408","author":"Xie","year":"2025","journal-title":"Atherosclerosis"},{"issue":"4","key":"10.1016\/j.atherosclerosis.2026.121912_bib11","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.jclinepi.2007.11.008","article-title":"The strengthening the reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"61","author":"von Elm","year":"2008","journal-title":"J Clin Epidemiol"},{"issue":"1","key":"10.1016\/j.atherosclerosis.2026.121912_bib12","doi-asserted-by":"crossref","DOI":"10.1186\/s12944-026-02897-3","article-title":"Real-world effectiveness and cardiovascular outcomes of PCSK9 inhibitor therapy: a prospective registry study","volume":"25","author":"Kafol","year":"2026","journal-title":"Lipids Health Dis"},{"key":"10.1016\/j.atherosclerosis.2026.121912_bib13","article-title":"High lipoprotein(a): actionable strategies for risk assessment and mitigation","volume":"18","author":"Reyes-Soffer","year":"2024","journal-title":"Am J Prev Cardiol"},{"issue":"1","key":"10.1016\/j.atherosclerosis.2026.121912_bib14","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1161\/ATVBAHA.119.312951","article-title":"Lipoprotein(a)-Lowering by 50 mg\/dL (105 nmol\/L) May be needed to reduce cardiovascular disease 20% in secondary prevention: a population-based Study","volume":"40","author":"Madsen","year":"2020","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"12","key":"10.1016\/j.atherosclerosis.2026.121912_bib15","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1161\/CIRCULATIONAHA.118.037184","article-title":"Lipoprotein(a), PCSK9 inhibition, and cardiovascular risk","volume":"139","author":"O'Donoghue","year":"2019","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.atherosclerosis.2026.121912_bib16","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.jacc.2019.10.057","article-title":"Effect of alirocumab on Lipoprotein(a) and cardiovascular risk after acute coronary syndrome","volume":"75","author":"Bittner","year":"2020","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"10.1016\/j.atherosclerosis.2026.121912_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.jacadv.2024.101549","article-title":"Impact of Proprotein Convertase Subtilisin\/Kexin type 9 inhibitors on Lipoprotein(a): a meta-analysis and meta-regression of randomized controlled trials","volume":"4","author":"Rivera","year":"2025","journal-title":"JACC Adv"},{"issue":"16","key":"10.1016\/j.atherosclerosis.2026.121912_bib18","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1912387","article-title":"Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol","volume":"382","author":"Ray","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.atherosclerosis.2026.121912_bib19","article-title":"Effect of inclisiran on lipoprotein(a) values: a meta-analysis","volume":"407","author":"Ena","year":"2025","journal-title":"Atherosclerosis"},{"issue":"1","key":"10.1016\/j.atherosclerosis.2026.121912_bib20","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1186\/s12967-025-07432-z","article-title":"Translating the effect of dual lipid reduction with PCSK9 inhibitors on a mechanical vascular instrumental biomarker in familial hypercholesterolemia subjects","volume":"23","author":"Bosco","year":"2025","journal-title":"J Transl Med"},{"issue":"5","key":"10.1016\/j.atherosclerosis.2026.121912_bib21","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/s11883-022-01008-8","article-title":"PCSK9 inhibitors in real-world practice: analysis of data from 314 patients and 2 years of experience in a Center of preventive cardiology","volume":"24","author":"Altschmiedova","year":"2022","journal-title":"Curr Atheroscler Rep"},{"issue":"4","key":"10.1016\/j.atherosclerosis.2026.121912_bib22","doi-asserted-by":"crossref","DOI":"10.3390\/jcdd9040101","article-title":"Acute effect of evolocumab on Lipoprotein(a) level and inflammation in patients with coronary artery disease","volume":"9","author":"Choi","year":"2022","journal-title":"J Cardiovasc Dev Dis"},{"key":"10.1016\/j.atherosclerosis.2026.121912_bib23","doi-asserted-by":"crossref","DOI":"10.1093\/eurjpc\/zwaf734","article-title":"Impact of PCSK9 inhibitors on Lipoprotein(a) levels: a multi-center Study","author":"Bhatia","year":"2025","journal-title":"Eur J Prev Cardiol"}],"container-title":["Atherosclerosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915026012785?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915026012785?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T21:04:00Z","timestamp":1793221440000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0021915026012785"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":23,"alternative-id":["S0021915026012785"],"URL":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2026.121912","relation":{},"ISSN":["0021-9150"],"issn-type":[{"value":"0021-9150","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lipoprotein(a) reduction with PCSK9-targeting pharmacotherapy: A prospective real-world registry study","name":"articletitle","label":"Article Title"},{"value":"Atherosclerosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2026.121912","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"121912"}}